Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.8 USD | -0.52% | 0.00% | -22.13% |
Sales 2024 * | 116M 158M | Sales 2025 * | 137M 187M | Capitalization | 188M 256M |
---|---|---|---|---|---|
Net income 2024 * | -41M -55.96M | Net income 2025 * | -26M -35.48M | EV / Sales 2024 * | 1.51 x |
Net cash position 2024 * | 12.67M 17.3M | Net cash position 2025 * | 14.68M 20.03M | EV / Sales 2025 * | 1.26 x |
P/E ratio 2024 * |
-4.53
x | P/E ratio 2025 * |
-7.26
x | Employees | 330 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.57% |
Latest transcript on Akoya Biosciences, Inc.
1 day | -0.52% | ||
Current month | -18.98% | ||
1 month | -18.98% | ||
3 months | -21.65% | ||
6 months | +21.41% | ||
Current year | -22.13% |
Managers | Title | Age | Since |
---|---|---|---|
Brian McKelligon
CEO | Chief Executive Officer | 55 | 17-06-30 |
Johnny Ek
DFI | Director of Finance/CFO | 48 | 23-03-19 |
Pascal Bamford
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Shepler
CHM | Chairman | 67 | 15-10-31 |
Myla Lai-Goldman
BRD | Director/Board Member | 66 | 21-09-15 |
Director/Board Member | 67 | 19-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +6.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.8 | -0.52% | 93,172 |
24-04-25 | 3.82 | +0.26% | 88,258 |
24-04-24 | 3.81 | 0.00% | 103,157 |
24-04-23 | 3.81 | -2.31% | 85,659 |
24-04-22 | 3.9 | +2.63% | 63,480 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.13% | 188M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- AKYA Stock